Stephen M. Rosenthal

Stephen M. Rosenthal

Auto-generated profile, based on publicly available information

Stephen M. Rosenthal

Univ Calif San Francisco, San Francisco, CA 94143 USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Annual Review of Medicine
Verified
Journal Article
Open access
JLJanet Y. Lee
Janet Y. Lee
SRStephen M. Rosenthal
Stephen M. Rosenthal
Increasing numbers of transgender and gender-diverse (TGD) youth, from early puberty through late adolescence, are seeking medical services to bring their physical sex characteristics into alignment with their gender identity—their inner sense of self as male or female or elsewhere on the gender spectrum. Numerous studies, primarily of short- and medium-term duration (up to 6 years), demonstrate the clearly beneficial—even lifesaving—mental health impact of gender-affirming medical care in TGD youth. However, there are significant gaps in knowledge and challenges to such care. Long-term safety and efficacy studies are needed to optimize medical care for TGD youth.

1 May 2010 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
MRMoulay D. Rochdi
Moulay D. Rochdi
GVGabriel A. Vargas
Gabriel A. Vargas
ECEric Carpentier
Eric Carpentier
GOGeneviève Oligny-Longpré
Geneviève Oligny-Longpré
SCStanford Chen
Stanford Chen
MBMichel Bouvier
Michel Bouvier
Substitution of arginine-137 of the vasopressin type 2 receptor (V2R) for histidine (R137H-V2R) leads to nephrogenic diabetes insipidus (NDI), whereas substitution of the same residue to cysteine or leucine (R137C/L-V2R) causes the nephrogenic syndrome of inappropriate antidiuresis (NSIAD). These two diseases have opposite clinical outcomes. Still, the three mutant receptors were shown to share constitutive β-arrestin recruitment and endocytosis, resistance to vasopressin-stimulated cAMP production and mitogen-activated protein kinase activation, and compromised cell surface targeting, raising questions about the contribution of these phenomenons to the diseases and their potential treatments. Blocking endocytosis exacerbated the elevated basal cAMP levels promoted by R137C/L-V2R but not the cAMP production elicited by R137H-V2R, demonstrating that substitution of Arg137 to Cys/Leu, but not His, leads to constitutive V2R-stimulated cAMP accumulation that most likely underlies NSIAD. The constitutively elevated endocytosis of R137C/L-V2R attenuates the signaling and most likely reduces the severity of NSIAD, whereas the elevated endocytosis of R137H-V2R probably contributes to NDI. The constitutive signaling of R137C/L-V2R was not inhibited by treatment with the V2R inverse agonist satavaptan (SR121463). In contrast, owing to its pharmacological chaperone property, SR121463 increased the R137C/L-V2R maturation and cell surface targeting, leading to a further increase in basal cAMP production, thus disqualifying it as a potential treatment for patients with R137C/L-V2R-induced NSIAD. However, vasopressin was found to promote β-arrestin/AP-2-dependent internalization of R137H/C/L-V2R beyond their already elevated endocytosis levels, raising the possibility that vasopressin could have a therapeutic value for patients with R137C/L-V2R-induced NSIAD by reducing steady-state surface receptor levels, thus lowering basal cAMP production.

9 July 2019 in JMIR Research Protocols
Verified
Journal Article
Open access
JOJohanna Olson-Kennedy
Johanna Olson-Kennedy
YCYee-Ming Chan
Yee-Ming Chan
Robert GarofaloRobert Garofalo
Robert Garofalo
NSNorman Spack
Norman Spack
DCDiane Chen
Diane Chen
SRStephen Rosenthal
Stephen Rosenthal
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Transgender children and adolescents, those who experience incongruence between assigned sex at birth and internal gender identity, are a poorly understood and understudied population in the United States. Since 2008, medical care for transgender youth has generally followed guidelines developed by professional consensus given the paucity of empirical research, particularly in a U.S. setting. Objective: The objective of this research is to provide evidence-based data to inform clinical care for transgender youth. The study aims to: 1) evaluate the impact of gonadotropin-releasing hormone (GnRH) agonists administered for puberty suppression on mental health, psychological well-being, and metabolic and physiologic parameters including bone health in a cohort of children and adolescents (Tanner stages 2-4) with gender dysphoria, comparing baseline and follow-up assessments; and 2) evaluate the impact of gender-affirming hormones (e.g. estradiol, testosterone, etc.) administered for phenotypic gender transition on mental health, psychological well-being, and metabolic and physiologic parameters in a cohort of adolescents with gender dysphoria, comparing baseline and follow-up assessments. Methods: The study uses a longitudinal observational design to examine the outcomes of existing medical treatment protocols for gender dysphoria in two distinct cohorts: youth initiating puberty suppression and youth pursuing a phenotypic gender transition. Routine anthropometric and physiologic parameters are collected through chart abstraction, questionnaires, and research interviews throughout the 24-month study period. Audio computer-assisted self-interview (ACASI) and individual interview survey instruments are used to collect demographic, mental health, psychosocial, and behavioral data from parents and youth in the blocker cohort and only from youth in the gender-affirming hormone cohort at baseline, 6, 12, 18, and 24 months. Results: Participant recruitment commenced in July 2016 and enrollment was completed in September 2018. Ninety participants were enrolled in the blocker cohort, and 301 participants in the gender affirming hormone cohort. Findings based on baseline data are expected to be submitted for publication in 2019. Results: Participant recruitment commenced in July 2016 and enrollment was completed in September 2018. Ninety participants were enrolled in the blocker cohort, and 301 participants in the gender affirming hormone cohort. Findings based on baseline data are expected to be submitted for publication in 2019. Conclusions: This longitudinal, observational study is collecting critical data on the existing models of care for transgender youth that have been used in clinical settings for close to a decade, though with limited empirical research to support them. This research is a direct response to the Institute of Medicine report calling for such studies, as well as the needs of clinicians and patients. Results from this study have the potential to significantly impact the medical and mental health services provided to transgender youth by making available rigorous scientific evidence describing the impact and safety of early treatment based on sexual development stage. Ultimately, we aim to understand if early medical intervention reduces the health disparities well-known to disproportionately affect transgender individuals across the lifespan.

2 July 2020 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
JLJanet Y Lee
Janet Y Lee
CFCourtney Finlayson
Courtney Finlayson
JOJohanna Olson-Kennedy
Johanna Olson-Kennedy
Robert GarofaloRobert Garofalo
Robert Garofalo
YCYee-Ming Chan
Yee-Ming Chan
SRStephen M Rosenthal
Stephen M Rosenthal
Context: Transgender youth may initiate GnRH agonists (GnRHa) to suppress puberty, a critical period for bone-mass accrual. Low bone mineral density (BMD) has been reported in late-pubertal transgender girls before gender-affirming therapy, but little is known about BMD in early-pubertal transgender youth. Objective: To describe BMD in early-pubertal transgender youth. Design: Cross-sectional analysis of the prospective, observational, longitudinal Trans Youth Care Study cohort. Setting: Four multidisciplinary academic pediatric gender centers in the United States. Participants: Early-pubertal transgender youth initiating GnRHa. Main Outcome Measures: Areal and volumetric BMD Z-scores. Results: Designated males at birth (DMAB) had below-average BMD Z-scores when compared with male reference standards, and designated females at birth (DFAB) had below-average BMD Z-scores when compared with female reference standards except at hip sites. At least 1 BMD Z-score was < -2 in 30% of DMAB and 13% of DFAB. Youth with low BMD scored lower on the Physical Activity Questionnaire for Older Children than youth with normal BMD, 2.32 ± 0.71 vs. 2.76 ± 0.61 (P = 0.01). There were no significant deficiencies in vitamin D, but dietary calcium intake was suboptimal in all youth. Conclusions: In early-pubertal transgender youth, BMD was lower than reference standards for sex designated at birth. This lower BMD may be explained, in part, by suboptimal calcium intake and decreased physical activity–potential targets for intervention. Our results suggest a potential need for assessment of BMD in prepubertal gender-diverse youth and continued monitoring of BMD throughout the pubertal period of gender-affirming therapy.

10 August 2021 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
SRStephen M. Rosenthal
Stephen M. Rosenthal

1 January 2016 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
SRStephen M. Rosenthal
Stephen M. Rosenthal
In many countries throughout the world, increasing numbers of gender nonconforming/transgender youth are seeking medical services to enable the development of physical characteristics consistent with their experienced gender. Such medical services include use of agents to block endogenous puberty at Tanner stage II with subsequent use of cross-sex hormones, and are based on longitudinal studies demonstrating that those individuals who were first identified as gender dysphoric in early or middle childhood and continue to meet the mental health criteria for being transgender at early puberty are likely to be transgender as adults. This review addresses terms and definitions applicable to gender nonconforming youth, studies that shed light on the biologic determinants of gender identity, current clinical practice guidelines for transgender youth, challenges to optimal care, and priorities for research.